Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 174

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival

Gallagher, David J., Kemeny, Nancy E. · 2009 · Journal of Clinical Oncology

Abstract

“Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases,” with great interest. This study confirmed that pathologic response to preoperative chemotherapy predicts survival for patients with colorectal hepatic metastases, establishing pathologic response as a prognostic indicator and as a potential end point in clinical trials evaluating neoadjuvant chemotherapy. However, we are concerned by the omission of adjuvant chemotherapy in the survival analysis. Patients with colorectal hepatic metastases are frequently treated with both pre- and postoperative chemotherapy, an approach that is supported by the European Organisation for Research and Treatment of Cancer 40983 trial. In this study, 364 patients with resectable colorectal hepatic metastases were randomized to six cycles of neoadjuvant infusional fluorouracil/leucovorin (FOLFOX4) plus six cycles of adjuvant FOLFOX4 versus surgery alone, resulting in a 9.2% improvement in 3-year diseasefree survival for the group that received perioperative chemotherapy and were resected (P .03). 2 Unfortunately, we do not know if both neoadjuvant and adjuvant approaches are necessary, and to date no clinical trial has addressed this issue. In the study by Blazer et al, 1 197 (64.6%) of 305 patients received adjuvant chemotherapy after hepatic resection, with a median time to treatment of 7 weeks and a median duration of adjuvant chemotherapy of 12 weeks. However, adjuvant chemotherapy is not included as a variable in the univariate or multivariate models reported in the article. One of the inherent flaws of constructing a prognostic model from retrospective data is that it is difficult to include all known clinical predictive markers, but the omission of adjuvant chemotherapy from the survival analysis is important. Its inclusion could alter the results. The benefit of adjuvant chemotherapy after resection of colorectal hepatic metastases has been reported. In a multivariate analysis, adjuvant chemotherapy and size of metastases were significantly associated with overall survival (OS; hazard ratio [HR] for surgery alone 1.39; 95% CI, 1.00 to 1.93; P .046; HR for two or more metastases 1.49; 95% CI, 1.06 to 2.11; P .023). 3 A retrospective review of 792 patients added further support for the importance of adjuvant chemotherapy. 4 Even for poor-risk patients (four or more bilobar metastases) adjuvant chemotherapy improved OS compared with surgery alone (51.5 months v 23 months; P .01), 5 and for patients with synchronous disease, treatment with postoperative fluorouracil or hepatic arterial infusion floxuridine-based therapy demonstrated improved OS compared with surgery alone (HR 0.62; 95% CI, 0.50 to 0.78; HR 0.51; 95% CI, 0.28 to 0.97, respectively). 6 Three randomized studies showed an increase in disease-free survival with the use of hepatic arterial infusion and systemic therapy after liver resection. 7-9 In our opinion, this data mandates the inclusion of adjuvant chemotherapy in any multivariate model investigating survival. We recently reported that radiologic response to neoadjvuant chemotherapy did not correlate with OS in patients with operable synchronous colorectal hepatic metastases. 10 In our univariate analysis, response to neoadjuvant chemotherapy was not associated with OS, and in the multivariate Cox model, only margins, stage of primary and postoperative carcinoembryonic antigen 5 ng/dL were significant (P .04, P .03, and P .01, respectively). For patients who progressed on neoadjuvant chemotherapy, there was a trend towards improved 5-year OS for those who received adjuvant hepatic arterial infusion chemotherapy. An association between pathological response to neoadjuvant chemotherapy and survival is not a new concept. It is well established, for example, in the management of muscle-invasive urothelial carcinoma, and it is likely that the association reported in this study is true. 11 However, we believe that a survival analysis must consider the impact of adjuvant chemotherapy and are interested to learn if its inclusion in the univariate and multivariate models in the Blazer et al 1 study changes the results. It would also be of clinical interest to test if duration of chemotherapy was related to pathologic response, and if predictors of complete response such as burden of disease can be identified. We would also welcome a comment from the authors on why different cutoff points were used for carcinoembryonic antigen (200 ng/mL v 5 ng/mL), and tumor size (5 cm v 3 cm) and number (multiple/solitary v 3/ 4) in the two analyses. There was a high death rate (8%) in the postoperative period. Was there an association between type of neoadjuvant chemotherapy used and postoperative death? Lastly, as we saw in our study, some patients who progress on neoadjuvant chemotherapy appear to be responsive with adjuvant salvage treatment. It would be interesting to know how many of the 149 patients (

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2009.22.4626

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 174

Metadata

Authors
Gallagher, D. J., & Kemeny, N. E.
Venue
Journal of Clinical Oncology
Published
2009-07-10
Volume
27
Issue
20
Pages
e18-e19
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2130841637
Cited by
174
References
1
FWCI
23.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival. https://app.cochat.ai/papers/10.1200/jco.2009.22.4626
The paper
Gallagher, D. J., & Kemeny, N. E. (2009). Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.22.4626

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.